Canterbury District Health Board (CDHB) and Sysmex New Zealand’s strategic partnership has gone from strength to strength, as both organisations faced the extra pressures brought about by the COVID-19 pandemic. With the urgent need to scale up testing and reporting at CDHB’s Canterbury Health Laboratories (CHL), the Sysmex New Zealand team were able to support […]

Our thoughts and prayers are with the families of those who have perished as a result of the novel coronavirus (COVID-19), and we offer our heartfelt sympathy to the patients currently suffering from this disease. We are truly grateful for the efforts of the medical community and all others who are working on the front lines to stop this pandemic from spreading. Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has decided to donate ¥30 million to the Kobe City Support Fund for Medical Professionals to support measures for countering COVID-19.

The City of Kobe (Location: Kobe, Japan; Mayor: Kizo Hisamoto), Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and SRL, Inc. (HQ: Shinjuku-ku, Tokyo, Japan; President and CEO: Shunichi Higashi), a subsidiary of Miraca Holdings Inc., hereby provide notice of the configuration of a PCR testing system within the Kobe Biomedical Innovation Cluster for the novel coronavirus (COVID-19). Operations are slated to commence on June 1, 2020.

Within hours of New Zealand lifting to alert level 4, a collaborative project was initiated between the Institute of Environmental Science and Research (ESR) and Sysmex New Zealand to establish a national clinical data repository (CDR) for all COVID-19 test reports from testing lab facilities across the country. ESR provide an extensive range of scientific […]

Prospective study to assess the feasibility and clinical utility of comprehensive genomic profiling at the time of initial treatment of patients with solid tumors.

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has obtained first marketing approval in Japan for an in vitro diagnostic medical device, “2019-nCoV Fluorescence Detection Real-Time RT-PCR Kit”. Delivery of this product to medical institutions is scheduled for March 2020.

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) provides notice that Dr. Yu Sunakawa, Associate Professor in the Department of Clinical Oncology at the St. Marianna University School of Medicine, presented his research findings at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2020 (ASCO-GI 2020), held in San Francisco, California, the United States, from January 23 to 25, 2020.

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and the Kobe City Eye Hospital (Location: Kobe, Japan; Director: Yasuo Kurimoto) announce that they have entered into a comprehensive collaboration agreement related to the clinical implementation of genomic medicine for hereditary retinal degenerative diseases. The agreement was signed in February 2020.

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and RIKEN Innovation Co., Ltd. (HQ: Saitama, Japan; President and CEO: Yoshihiro Aburatani) have signed a partnership agreement to use the research results from National Research and Development Institute RIKEN (HQ: Saitama, Japan; President: Hiroshi Matsumoto) to jointly create new businesses and return benefits to society.

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has reached an agreement to invest in Astrego Diagnostics AB (HQ: Uppsala, Sweden; CEO: Ove Öhman). Through this investment, Sysmex aims to help commercialize a rapid drug susceptibility test that Astrego is developing for urinary tract infections.

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) received regulatory approval on December 9, 2019 from China’s National Medical Products Administration (NMPA) for LYNOAMP™ BC, an in vitro diagnostic reagent. Our system to test for breast cancer lymph node metastasis using the OSNA™ method has received Class III1 regulatory approval as the first product for lymph node metastasis testing using a molecular biological technique.